A phase II trial using etanercept, a recombinant tumour necrosis factor antagonist, in metastatic breast cancer - Forster, MD; Braybrooke, J; Madhusudan, S; Kaur, K; Hoare, S; Balkwill, F; Ganesan, T; Talbot, D; Harris, A (BRITISH JOURNAL OF CANCER, 2002)